Spero Therapeutics Analyst Ratings
BenzingaApr 4 09:44 ET
Spero Therapeutics Analyst Ratings
BenzingaMar 18 07:01 ET
Spero Therapeutics' Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating
TipRanksMar 18 06:26 ET
TD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)
TipRanksMar 13 23:25 ET
TD Cowen Keeps Their Hold Rating on Spero Therapeutics (SPRO)
TipRanksNov 17, 2023 14:25 ET
Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Spero Therapeutics (SPRO) and EFFECTOR Therapeutics (EFTR)
TipRanksNov 14, 2023 06:40 ET
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
BenzingaNov 14, 2023 06:31 ET
Spero Therapeutics Analyst Ratings
BenzingaNov 14, 2023 06:30 ET
Buy Rating for Spero Therapeutics: Impact of New CFO and Imminent Phase 3 Trial Program
TipRanksNov 2, 2023 14:53 ET
Spero Therapeutics (SPRO) Receives a Buy From H.C. Wainwright
TipRanksSep 5, 2023 06:25 ET
Spero Therapeutics Analyst Ratings
BenzingaSep 5, 2023 06:14 ET
Spero Therapeutics Analyst Ratings
BenzingaAug 14, 2023 06:21 ET
H.C. Wainwright Reaffirms Their Buy Rating on Spero Therapeutics (SPRO)
TipRanksAug 1, 2023 06:25 ET
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target
BenzingaAug 1, 2023 06:22 ET
Spero Therapeutics Analyst Ratings
BenzingaAug 1, 2023 06:21 ET
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target
BenzingaJul 20, 2023 06:40 ET
Spero Therapeutics Analyst Ratings
BenzingaJul 20, 2023 06:39 ET
Spero Therapeutics (SPRO) Receives a Buy From H.C. Wainwright
TipRanksJul 20, 2023 06:15 ET
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target
BenzingaApr 10, 2023 09:41 ET
H.C. Wainwright Sticks to Its Buy Rating for Spero Therapeutics (SPRO)
TipRanksApr 10, 2023 08:51 ET
No Data
No Data